Aspivix
Company Details
Status: Private
Employees: 1-10
Location:
Route de la Corniche 8, 1066 Epalinges
Type:
sample
sample
Technology:
sample
About: Aspivix is a medical device company in women’s health, based in Switzerland, developing next-generation devices for gynecology.
Our flagship product, Carevix™, is the world’s first suction cervical stabilizer clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynecology, including IUD insertion, hysteroscopy, cervical biopsies, fertility treatments, and more.
Carevix™ is a medical device that has received in 2023 FDA-clearance for the US market, as well as the CE-Mark for the European countries. Carevix™ study published in the international journal, Contraception, in March 2023 demonstrated superiority over the use of a single tooth tenaculum, reducing the pain by up to 73% and the bleeding by up to 83% in IUD insertions.
More than 120 million women worldwide have procedures using the antiquated single-tooth tenaculum, an instrument invented over a century ago, without consideration of a woman's anatomy or pain, and yet it is still considered to be the standard of care in gynecology.
At Aspivix, we think women deserve more. We are driven by our vision to make gynecology modern.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Aspivix | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.